Ming-Huang Chen
Overview
Explore the profile of Ming-Huang Chen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
164
Citations
1853
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ho I, Chiang N, Lai J, Chang P, Chen S, Hung Y, et al.
Oncologist
. 2025 Mar;
30(3).
PMID: 40063612
Background: Neuroendocrine carcinoma (NEC) is an aggressive, poorly differentiated Grade 3 (G3) tumor with high nuclear and cellular atypia and Ki-67 indices over 20%. While most cases are lung NECs,...
2.
Huang C, Liu G, Yeh Y, Chung S, Chang Y, Chiang N, et al.
J Transl Med
. 2025 Feb;
23(1):218.
PMID: 39984938
Background: Gastrointestinal (GI) cancers account for more than one-third of cancer-related mortality, and the prognosis for late-stage patients remains poor. Immunotherapy has been proven to extend the survival of patients...
3.
Chen S, Ho H, Liu C, Hung Y, Chiang N, Chen M, et al.
BMC Cancer
. 2025 Feb;
25(1):199.
PMID: 39905360
Background: Alpha-fetoprotein (AFP) is a key biomarker for hepatocellular carcinoma (HCC), but 30-40% of cases are AFP-negative. Prothrombin induced by vitamin K absence II (PIVKA-II) is more sensitive for HCC...
4.
Chung S, Yeh Y, Huang C, Chiang N, Hsu D, Chan M, et al.
J Immunother Cancer
. 2025 Jan;
13(1).
PMID: 39870490
Background: Cholangiocarcinoma is a challenging malignancy with limited responses to conventional therapies, particularly immune checkpoint inhibitor therapy. Tumor-infiltrating lymphocytes (TILs) and tertiary lymphoid structures (TLSs) are key components of the...
5.
Chiu Y, Kung C, Huang K, Lin S, Fang W, Chen M, et al.
J Chin Med Assoc
. 2025 Jan;
PMID: 39792654
Background: Few studies have explored the genetic changes and clinicopathological features of stage II/III gastric cancer (GC) patients with no tumor recurrence, early recurrence, or late recurrence after curative surgery....
6.
Tang C, Lin Y, Yeh Y, Chung S, Chang Y, Hung Y, et al.
Cancer Immunol Immunother
. 2025 Jan;
74(2):41.
PMID: 39751894
In our previous phase II T1219 trial for advanced biliary tract cancer (ABTC), the combination of nivolumab with modified gemcitabine and S-1 exhibited promising efficacy, while the programmed-death-ligand-1 (PD-L1) expression...
7.
Hung Y, Lee P, Chang Y, Yang M, Chiu C, Chen M, et al.
Aliment Pharmacol Ther
. 2024 Nov;
61(3):501-512.
PMID: 39582238
Background: Notable advances have been made in immune checkpoint inhibitors (ICIs) for cancer treatment. However, the adverse effects of ICIs, especially hepatotoxicity, remain a challenging problem. Whether patients in hepatitis...
8.
Lai K, Chen Y, Hung Y, Chiang N, Chen M, Chen S
Hepatol Int
. 2024 Nov;
18(6):1804-1814.
PMID: 39580565
Background/purpose: Recently, anti-programmed cell death protein-1 (anti-PD-1) and anti-PD-L1 therapies were approved for hepatocellular carcinoma (HCC). However, the effectiveness of rechallenging with one immune checkpoint inhibitor (ICI) after failure of...
9.
Huang W, Tang Y, Wu C, Hou M, Hsu H, Su P, et al.
Oncologist
. 2024 Nov;
PMID: 39566070
Background: Biliary tract cancer (BTC) is an aggressive biliary tract cancer, arising from the bile ducts and gallbladder, with a poor prognosis. The TOPAZ-1 trial of durvalumab plus first-line chemotherapy...
10.
Macarulla T, Ren Z, Chon H, Park J, Kim J, Pressiani T, et al.
J Clin Oncol
. 2024 Oct;
43(5):545-557.
PMID: 39423355
Purpose: Biliary tract cancers (BTCs) harbor an immunosuppressed tumor microenvironment and respond poorly to PD-1/PD-L1 inhibitors. Bevacizumab (anti-vascular endothelial growth factor) plus chemotherapy can promote anticancer immunity, augmenting response to...